Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SNN
stocks logo

SNN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
1.51B
+6.84%
--
--
1.67B
+6.29%
--
--
1.48B
+5.19%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Smith & Nephew plc (SNN) for FY2025, with the revenue forecasts being adjusted by 0.02% over the past three months. During the same period, the stock price has changed by -14.07%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.02%
In Past 3 Month
Stock Price
Go Down
down Image
-14.07%
In Past 3 Month
Wall Street analysts forecast SNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNN is 36.05 USD with a low forecast of 34.65 USD and a high forecast of 37.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast SNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNN is 36.05 USD with a low forecast of 34.65 USD and a high forecast of 37.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
0 Sell
Hold
Current: 32.730
sliders
Low
34.65
Averages
36.05
High
37.50
Current: 32.730
sliders
Low
34.65
Averages
36.05
High
37.50
Canaccord
Hold
downgrade
$36 -> $34
2025-11-11
Reason
Canaccord
Price Target
$36 -> $34
2025-11-11
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Smith & Nephew to $34 from $36 and keeps a Hold rating on the shares. The firm updated its model followong Q3 results and noted the company reiterated its expectations to deliver 5% underlying growth and reiterated its trading profit margin expectations to be between 19.0% and 20.0%, with a stronger margin anticipated in the 2H versus 1H as it works to deliver on operational savings and believes China headwinds should decrease.
Morgan Stanley
NULL -> Overweight
maintain
2025-11-10
Reason
Morgan Stanley
Price Target
2025-11-10
maintain
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Smith & Nephew to 1,563 GBp from 1,547 GBp and keeps an Overweight rating on the shares.
RBC Capital
Jack Reynolds-Clark
maintain
2025-10-20
Reason
RBC Capital
Jack Reynolds-Clark
Price Target
2025-10-20
maintain
Reason
RBC Capital analyst Jack Reynolds-Clark raised the firm's price target on Smith & Nephew to 1,700 GBp from 1,400 GBp and keeps an Outperform rating on the shares.
Bernstein
Outperform
to
Market Perform
downgrade
$37.50
2025-10-14
Reason
Bernstein
Price Target
$37.50
2025-10-14
downgrade
Outperform
to
Market Perform
Reason
Bernstein downgraded Smith & Nephew to Market Perform from Outperform with a $37.50 price target. Smith & Nephew's stock has seen a strong rally in 2025 year-to-date based on solid revenue growth and an inflection in Orthopedic profitability, the firm notes. With consensus 2026 EPS now 10% higher than at the start of the year, coupled with a recent recovery in valuation, Bernstein is moving to the sidelines.
Rothschild & Co Redburn
Neutral
maintain
2025-09-18
Reason
Rothschild & Co Redburn
Price Target
2025-09-18
maintain
Neutral
Reason
Rothschild & Co Redburn raised the firm's price target on Smith & Nephew to 1,445 GBp from 1,270 GBp and keeps a Neutral rating on the shares. The firm sees competitive challenges in the company's orthopedics segment offsetting improved execution and strength in sports medicine.
Canaccord
Caitlin Cronin
Hold
maintain
$28 -> $36
2025-08-18
Reason
Canaccord
Caitlin Cronin
Price Target
$28 -> $36
2025-08-18
maintain
Hold
Reason
Canaccord analyst Caitlin Cronin raised the firm's price target on Smith & Nephew to $36 from $28 and keeps a Hold rating on the shares. The firm updated its model following Q2 results noting FY25 guidance was unchanged, including continued expectations for 5% underlying growth and proforma trading margins in the range of 19-20%.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Smith & Nephew PLC (SNN.N) is 19.59, compared to its 5-year average forward P/E of 17.71. For a more detailed relative valuation and DCF analysis to assess Smith & Nephew PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
17.71
Current PE
19.59
Overvalued PE
21.12
Undervalued PE
14.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
10.98
Current EV/EBITDA
9.91
Overvalued EV/EBITDA
12.78
Undervalued EV/EBITDA
9.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.39
Current PS
2.21
Overvalued PS
2.92
Undervalued PS
1.87
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 225.8% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SNN News & Events

Events Timeline

(ET)
2025-10-22
11:33:16
Smith & Nephew and UFC Extend Partnership with Multi-Year Agreement
select
2025-09-11 (ET)
2025-09-11
08:17:48
Smith & Nephew Reveals New Findings and Market Insights on REGENETEN
select
2025-09-03 (ET)
2025-09-03
10:18:15
Smith & Nephew Reveals CENTRIO Platelet-Rich Plasma System Launch in the U.S.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-27Globenewswire
Sintana Secures 75% Shareholder Approval for Challenger Acquisition
  • Acquisition Agreement: Sintana and the Independent Challenger Directors have reached an agreement for Sintana to acquire all ordinary shares of Challenger, indicating a proactive strategy for business expansion and asset consolidation.
  • Shareholder Voting Results: At the General Meeting on November 26, 2025, over 75% of Scheme Shareholders voted in favor of the scheme, reflecting strong investor confidence in the acquisition, which is expected to enhance Sintana's market position.
  • Clear Next Steps: The acquisition completion is still subject to court approval, anticipated to become effective on December 11, 2025, ensuring Sintana's strategic flexibility in future business integration and resource allocation.
  • Market Reaction Anticipated: Sintana plans to seek AIM listing post-acquisition, which is expected to enhance its visibility in capital markets and financing capabilities, thereby supporting future expansion and investment initiatives.
[object Object]
Preview
2.0
11-06NASDAQ.COM
Smith & Nephew (SNN) Has Reached Oversold Levels

  • Stock Performance: Smith & Nephew plc (SNN) shares have entered oversold territory with an RSI of 27.8, indicating potential exhaustion of recent selling pressure.

  • Price Range: The 52-week low for SNN is $23.69, while the high is $38.79, with the last trade recorded at $32.38.

  • Market Comparison: The current RSI of the S&P 500 ETF (SPY) is 48.4, suggesting that SNN is significantly lower in relative strength.

  • Investment Outlook: Bullish investors may view the low RSI as an opportunity to consider buying SNN shares as selling pressure diminishes.

[object Object]
Preview
3.5
10-27Newsfilter
Smith+Nephew Comparative Study Reveals PICO◊ sNPWT (-80 mmHg) Outperforms PrevenaTM -125 mmHg sNPWT in Reducing Wound Dehiscence and Healthcare Costs in Cardiovascular and Orthopedic Surgery

  • Study Findings: A comparative study by Smith+Nephew reveals that the PICO single-use negative pressure wound therapy (sNPWT) device significantly reduces wound dehiscence, hospital length of stay, and healthcare costs compared to the Prevena sNPWT device in orthopedic and cardiovascular surgeries.

  • Impact on Surgical Outcomes: The study, analyzing data from over 22,000 patients, shows a 57.8% reduction in wound dehiscence risk and a 9.1% reduction in hospital stay for cardiovascular surgeries, while orthopedic surgeries saw a 63.9% reduction in wound dehiscence and a 29.7% reduction in length of stay.

  • Economic Benefits: The use of PICO sNPWT resulted in substantial cost savings, with reductions in admission-related costs and expenditures within three months post-surgery, highlighting its potential to alleviate strain on healthcare resources.

  • Growing Evidence: These findings align with global recommendations for the prophylactic use of incisional negative pressure wound therapy (iNPWT) to minimize surgical site infections, reinforcing its importance in surgical practices for at-risk patients.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Smith & Nephew PLC (SNN) stock price today?

The current price of SNN is 32.73 USD — it has decreased -0.7 % in the last trading day.

arrow icon

What is Smith & Nephew PLC (SNN)'s business?

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

arrow icon

What is the price predicton of SNN Stock?

Wall Street analysts forecast SNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNN is 36.05 USD with a low forecast of 34.65 USD and a high forecast of 37.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Smith & Nephew PLC (SNN)'s revenue for the last quarter?

Smith & Nephew PLC revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Smith & Nephew PLC (SNN)'s earnings per share (EPS) for the last quarter?

Smith & Nephew PLC. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Smith & Nephew PLC (SNN)'s fundamentals?

The market is revising Upward the revenue expectations for Smith & Nephew plc (SNN) for FY2025, with the revenue forecasts being adjusted by 0.02% over the past three months. During the same period, the stock price has changed by -14.07%.
arrow icon

How many employees does Smith & Nephew PLC (SNN). have?

Smith & Nephew PLC (SNN) has 17349 emplpoyees as of December 05 2025.

arrow icon

What is Smith & Nephew PLC (SNN) market cap?

Today SNN has the market capitalization of 13.89B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free